Company news
SIGA Technologies Inc. news in 2022
SIGA Technologies Inc.'s news releases, calls and decks from 2022, newest first.
SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2022
November 2, 2022
SIGA Technologies to Host Business Update Call on November 3rd, 2022 Following Release of Third Quarter 2022 Financial Results
October 26, 2022
SIGA Provides Update on Progress in Clinical Trials to Assess Use of TPOXX ® (tecovirimat) for Treatment of Monkeypox
October 11, 2022
SIGA Technologies Announces New Contract Awarded by U.S. Department of Defense for the Procurement of up to $10.7 Million of Oral TPOXX®
September 28, 2022
SIGA Announces Approximately $16 Million of International Procurement Orders Received in August and Early September for Oral TPOXX® (Tecovirimat)
September 25, 2022
SIGA Announces BARDA Exercise of Procurement Options Valued at Approximately $26 Million for IV TPOXX®
August 8, 2022
SIGA Reports Financial Results for Three and Six Months Ended June 30, 2022
August 3, 2022
SIGA Technologies to Host Business Update Call on August 4th, 2022 Following Release of Second Quarter 2022 Financial Results
July 27, 2022
SIGA Announces Oncology Collaboration with KaliVir Immunotherapeutics
July 14, 2022
SIGA Announces Approximately $28 Million of International Procurement Orders for Oral TPOXX® (Tecovirimat)
July 11, 2022
SIGA Technologies Receives Approval from UK for Tecovirimat
July 7, 2022
SIGA Announces $13 Million of International Procurement Orders for Oral TPOXX® (Tecovirimat)
June 22, 2022
SIGA to Participate in Alliance Global Partners’ Monkeypox Panel on Thursday, June 23rd 2022
June 21, 2022
SIGA Receives Approval from the FDA for Intravenous (IV) Formulation of TPOXX® (tecovirimat)
May 18, 2022
New Contract Awarded by U.S. Department of Defense for the Procurement of up to Approximately $7.5 Million of Oral TPOXX®
May 11, 2022
SIGA Reports Financial Results for Three Months Ended March 31, 2022
May 4, 2022
SIGA Declares Special Dividend of $0.45 Per Share
May 4, 2022
SIGA Technologies to Host Business Update Call on May 5th, 2022 Following Release of First Quarter 2022 Financial Results
April 27, 2022
SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2021
March 2, 2022
SIGA Announces Start of TPOXX® Post-Exposure Prophylactic (“PEP”) Clinical Trials
March 1, 2022
SIGA Technologies to Host Business Update Call on March 3rd, 2022 Following Release of Fourth Quarter and Full Year 2021 Financial Results
February 23, 2022
SIGA Announces Preclinical Oncology Research Collaboration with Bioarchitech
January 24, 2022
SIGA Technologies to Participate in Edison Group’s Global Healthcare “Open House” Virtual Conference from January 25-27th, 2022
January 17, 2022
SIGA Technologies Receives Approval from the European Medicines Agency for Tecovirimat
January 9, 2022